30. Materials and methods are available as supplementary materials on Science Online. 31. T. A. Dumitru, I. R. Duddy, P. F. Green, Geology 22, 499 (1994 Dan Doherty, 2, 3 Joshua M. Akey, 1 Raphael Bernier, 4 Evan E. Eichler, 1, 7 * Jay Shendure 1 * Exome sequencing studies of autism spectrum disorders (ASDs) have identified many de novo mutations but few recurrently disrupted genes. We therefore developed a modified molecular inversion probe method enabling ultra-low-cost candidate gene resequencing in very large cohorts.
To demonstrate the power of this approach, we captured and sequenced 44 candidate genes in 2446 ASD probands. We discovered 27 de novo events in 16 genes, 59% of which are predicted to truncate proteins or disrupt splicing. We estimate that recurrent disruptive mutations in six genes-CHD8, DYRK1A, GRIN2B, TBR1, PTEN, and TBL1XR1-may contribute to 1% of sporadic ASDs. Our data support associations between specific genes and reciprocal subphenotypes (CHD8-macrocephaly and DYRK1A-microcephaly) and replicate the importance of a b-catenin-chromatin-remodeling network to ASD etiology.
T here is considerable interest in the contribution of rare variants and de novo mutations to the genetic basis of complex phenotypes such as autism spectrum disorders (ASDs). However, because of extreme genetic heterogeneity, the sample sizes required to implicate any single gene in a complex phenotype are extremely large (1) . Exome sequencing has identified hundreds of ASD candidate genes on the basis of de novo mutations observed in the affected offspring of unaffected parents (2-6). Yet, only a single mutation was observed in nearly all such genes, and sequencing of over 900 trios was insufficient to establish mutations at any single gene as definitive genetic risk factors (2) (3) (4) (5) (6) .
To address this, we sought to evaluate candidate genes identified by exome sequencing (2, 3) for de novo mutations in a much larger ASD cohort. We developed a modified molecular inversion probe (MIP) strategy (Fig. 1A ) (7-9) with novel algorithms for MIP design; an optimized, automatable work flow with robust performance and minimal DNA input; extensive multiplexing of samples while sequencing; and reagent costs of less than $1 per gene per sample. Extensive validation using several probe sets and sample collections demonstrated 99% sensitivity and 98% positive predictive value for single-nucleotide variants at well-covered positions, i.e., 92 to 98% of targeted bases (figs. S1 to S7 and tables S1 to S9) (10) .
We applied this method to 2494 ASD probands from the Simons Simplex Collection (SSC) (11) using two probe sets [ASD1 (6 genes) and ASD2 (38 genes)] to target 44 ASD candidate genes (12) . Preliminary results using ASD1 on a subset of the SSC implicated GRIN2B as a risk locus (3) . The 44 genes were selected from 192 candidates (2, 3) by focusing on genes with disruptive mutations, associations with syndromic autism (13), overlap with known or suspected neurodevelopmental copy number variation (CNV) risk loci (13, 14) , structural similarities, and/or neuronal expression (table S3) . Although a few of the 44 genes have been reported to be disrupted in individuals with neurodevelopmental or neuropsychiatric disorders (often including concurrent dysmorphologies), their role in socalled idiopathic ASDs has not been rigorously established. Twenty-three of the 44 genes intersect a 49-member b-catenin-chromatin-remodeling protein-protein interaction (PPI) network (2) or an expanded 74-member network (figs. S8 and S9) (3, 4) .
We required samples to successfully capture with both probe sets, yielding 2446 ASD probands with MIP data, 2364 of which had only MIP data and for 82 of which we had also sequenced their exomes (2, 3) . The high GC content of several candidates required considerable rebalancing to improve capture uniformity (12) (figs. S3A and S10). Nevertheless, the reproducible behavior of most MIPs allowed us to identify copy number variation at targeted genes, including several inherited duplications (figs. S11 and S12 and table S10).
To discover de novo mutations, we first identified candidate sites by filtering against variants observed in other cohorts, including non-ASD exomes and MIP-based resequencing of 762 healthy, non-ASD individuals (12) . The remaining candidates were further tested by MIP-based resequencing of the proband's parents and, if potentially de novo, confirmed by Sanger sequencing of the parent-child trio (10, 12) . We discovered 27 de novo mutations that occurred in 16 of the 44 genes ( Fig. 1 , B to E; Table 1; and table S11) . Consistent with an increased sensitivity for MIPbased resequencing, six of these were not reported in exome-sequenced individuals (Table 1 , tables S5 and S11, and fig. S13) (3, 4, 6) . Notably, the proportion of de novo events that are severely disruptive, i.e., coding indels, nonsense mutations, and splice-site disruptions (17/27 or 0.63), is four times the expected proportion for random de novo mutations (0.16, binomial P = 4.9 × 10 −8 ) (table S12) (15). Given their extremely low frequency, accurately establishing expectation for de novo mutations in a locus-specific manner through the sequencing of control trios is impractical. We therefore developed a probabilistic model that incorporates several factors: the overall rate of mutation in coding sequences, estimates of relative locusspecific rates based on human-chimpanzee fixed differences (fig. S14 and table S13), and other factors that may influence the distribution of mutation classes, e.g., codon structure (12) . We applied this model to estimate (by simulation) the probability of observing additional de novo mutations during MIP-based resequencing of the SSC cohort. To compare expectation and observation, we treated missense mutations as one class and severe disruptions as a second class. Thus, we could evaluate the probability at a given locus of observing at least x de novo mutations, of which at least y belong to the severe class. We found evidence of mutation burden-a higher rate of de novo mutation than expected-in the overall set of 44 genes (observed n = 27 versus mean expected n = 5.6, simulated P < 2 × 10 −9 ) ( Fig. 2A) . The burden was driven by the severe class (observed n = 17 versus mean expected n = 0.58, simulated P < 2 × 10
−9
). Most severe class mutations intersected the 74-member PPI network (16 out of 17), although only 23 out of 44 genes are in this network (binomial P = 0.0002) (12) . Furthermore, 21 out of 27 mutations occurred in network-associated genes (binomial P = 0.004). Of the six individual genes (CHD8, GRIN2B, DYRK1A, PTEN, TBR1, and TBL1XR1) with evidence of mutation burden [alpha of 0.05 after a Holm-Bonferroni correction for multiple testing (Fig. 2A) ; TBL1XR1 is borderline significant with a more conservative Bonferroni correction], five fall within the b-catenin-chromatin-remodeling network. In our combined MIP and exome data, 1% (24 out of 2573) of ASD probands harbor a de novo mutation in one of these six genes, with CHD8 representing 0.35% (9 out of 2573) (Fig.  1B and Table 1) .
For these analyses, we conservatively used the highest available empirical estimate of the overall mutation rate in coding sequences (3) . With the exception of TBL1XR, these results were robust to doubling the overall mutation rate or to using the upper bound of the 95% confidence interval of the locus-specific rate estimate for each of these genes (10) . Moreover, we obtained similar results regardless of whether parameters were estimated from rare, segregating variation or from de novo mutations in unaffected siblings (10) , as well as with a sequence composition model based on genome-wide de novo mutation (16) . Exome sequencing of non-ASD individuals (unaffected siblings or non-ASD cohorts) further supports these conclusions (table S14) (10) .
We also validated 23 inherited, severely disruptive variants in the 44 genes (table S15). Two probands with such variants carry de novo 16p11.2 duplications (table S16). Combining de novo and inherited events, severe class variants were observed at twice the rate in MIP-sequenced probands as compared with MIP-sequenced healthy, non-ASD individuals (Fisher's exact test, P = 0.083). Severe class variants were not transmitted to 14 out of 20 unaffected siblings (binomial P = 0.058) (table S15). However, larger cohorts than currently exist will be needed to fully evaluate these modest trends.
We analyzed phenotypic data on probands with mutations in the six implicated genes. Each was diagnosed with autism on the basis of current, strict, gold-standard criteria. No obvious dysmorphologies or recurrent comorbidities were present. Probands tended to fall into the intellectual disability range for nonverbal IQ (NVIQ) (mean 58.3) (Table 1) . However, for CHD8, probands were found to have NVIQ scores ranging from profoundly impaired to average (mean 62.2, range 19 to 98).
Given the previously observed microcephaly in our index DYRK1A mutation case, macrocephaly in both probands with CHD8 mutations (3), and the association of these traits with other syndromic loci (13, 17) , we reexamined head circumference (HC) in the larger set of probands with protein-truncation or splice-site de novo events using age-and sex-normalized HC Z scores (12) (Fig. 2B) . For CHD8 (n = 8), we observed significantly larger head sizes relative to individuals screened without CHD8 mutations (two-sample permutation test, two-sided P = 0.0007). De novo CHD8 mutations are present in~2% of macrocephalic (HC > 2.0) SSC probands (n = 366), which suggests a useful phenotype for patient subclassification. For DYRK1A (n = 3), we observed significantly smaller head sizes relative to individuals screened without DYRK1A mutations (two-sample permutation test, two-sided P = 0.0005). Comparison of head size in the context of the families (Fig. 2, C and D, and table S17) provides further support for this reciprocal trend (10) . These findings are also consistent with case reports of patients with structural rearrangements and mouse transgenic models that implicate DYRK1A and CHD8 as regulators of brain growth (18) (19) (20) (21) . Macrocephaly was also observed in individuals with de novo and inherited PTEN mutations (22) .
Our data support an important role for de novo mutations in six genes in~1% of sporadic ASDs. As the SSC was specifically established for simplex families and as its probands generally have higher cognitive functioning than has been reported in other ASD cohorts (11), it is unknown how our findings will translate into other cohorts. Furthermore, whereas our data implicate specific loci in ASDs, they are insufficient to evaluate whether the observed de novo mutations are sufficient to cause ASDs (tables S16 and S18).
Exome sequencing and CNV studies suggest that there are hundreds of relevant genetic loci for ASDs. Technologies and study designs directed at identifying de novo mutations, both for the discovery of ASD candidate genes, as well as for their validation, provide sufficient power to implicate individual genes from a relatively small number of events. The analytical framework described here can be applied to any other disorder-simple or complex-for which de novo coding mutations are suspected to contribute to risk. In addition, the experimental methods presented here are broadly useful for the rapid and economical resequencing of candidate www.sciencemag.org SCIENCE VOL 338 21 DECEMBER 2012 genes in extremely large cohorts, as may be required for the definitive implication of rare variants or de novo mutations in any genetically complex disorder.
Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell
Chenghang Zong, 1 * Sijia Lu, 1 * † Alec R. Chapman, 1,2 * X. Sunney Xie 1 ‡ Kindred cells can have different genomes because of dynamic changes in DNA. Single-cell sequencing is needed to characterize these genomic differences but has been hindered by whole-genome amplification bias, resulting in low genome coverage. Here, we report on a new amplification method-multiple annealing and looping-based amplification cycles (MALBAC)-that offers high uniformity across the genome. Sequencing MALBAC-amplified DNA achieves 93% genome coverage ≥1x for a single human cell at 25x mean sequencing depth. We detected digitized copy-number variations (CNVs) of a single cancer cell. By sequencing three kindred cells, we were able to identify individual single-nucleotide variations (SNVs), with no false positives detected. We directly measured the genome-wide mutation rate of a cancer cell line and found that purine-pyrimidine exchanges occurred unusually frequently among the newly acquired SNVs.
S
ingle-molecule and single-cell studies reveal behaviors that are hidden in bulk measurements (1, 2) . In a human cell, the genetic information is encoded in 46 chromosomes. The variations occurring in these chromosomes, such as single-nucleotide variations (SNVs) and copy-number variations (CNVs) (3) , are the driving forces in biological processes such as evolution and cancer. Such dynamic variations are reflected in the genomic heterogeneity among a population of cells, which demands characterization of genomes at the single-cell level (4-6). Single-cell genomics analysis is also necessary when the number of cells available is limited to few or one, such as prenatal testing samples (7, 8) , circulating tumor cells (9) , and forensic specimens (10) .
Prompted by rapid progress in next-generation sequencing techniques (11) , there have been several reports on whole-genome sequencing of single cells (12) (13) (14) (15) (16) . These methods have relied on whole-genome amplification (WGA) of an individual cell to generate enough DNA for sequencing (17-21). However, WGA methods in general are prone to amplification bias, which results in low genome coverage. Polymerase chain reaction (PCR)-based WGA introduces sequence-dependent bias because of the exponential amplification with random primers (17, 18, 22) . Multiple displacement amplification (MDA), which uses random priming and the strand-displacing f29 polymerase under isothermal conditions (19) , has provided improvements over PCR-based methods but still exhibits considerable bias, again due to nonlinear amplification.
Here we report a new WGA method, multiple annealing and looping-based amplification cycles (MALBAC), which introduces quasilinear preamplification to reduce the bias associated with nonlinear amplification. Picograms of DNA fragments (~10 to 100 kb) from a single human cell serve as templates for amplification with MALBAC (Fig. 1) . The amplification is initiated with a pool of random primers, each having a common 27-nucleotide sequence and 8 variable nucleotides that can evenly hybridize to the templates at 0°C. At an elevated temperature of 65°C, DNA polymerases with strand-displacement activity are used to generate semiamplicons with variable lengths (0.5 to 1.5 kb), which are then melted off from the template at 94°C. Amplification of the semiamplicons gives full amplicons that have complementary ends. The temperature is cycled to 58°C to allow the looping of full amplicons, which prevents further amplification and cross-hybridizations. Five cycles of preamplification are followed by exponential amplification of the full amplicons by PCR to generate micrograms of DNA required for next-generation sequencing (Fig. 1) . In the PCR, oligonucleotides with the common 27-nucleotide sequence are used as the primers.
We used MALBAC to amplify the DNA of single SW480 cancer cells. With~25x mean
